Global Peptide Cancer Vaccine Competitive Landscape Professional Research Report 2025
Description
Global Peptide Cancer Vaccine Competitive Landscape Professional Research Report 2025
Research Summary
A peptide cancer vaccine is an immunotherapeutic approach used in the field of cancer treatment and prevention. It is designed to stimulate the body＇s immune system to recognize and attack cancer cells by targeting specific proteins or peptides that are unique to those cancer cells. The vaccine typically contains a selected peptide or a combination of peptides derived from tumor-associated antigens, which are substances present on cancer cells but not on normal healthy cells. By introducing these peptides into the patient＇s body, the vaccine aims to trigger an immune response that targets and destroys cancer cells while sparing healthy tissues. Peptide cancer vaccines are considered a personalized and targeted therapy, as they can be customized to a patient＇s specific cancer type, and they hold promise for various cancer treatments, including melanoma and certain types of breast, prostate, and lung cancers. Clinical research and development in this field continue to explore the potential of peptide cancer vaccines as a complementary approach to traditional cancer treatments like surgery, chemotherapy, and radiation therapy.
According to DIResearch's in-depth investigation and research, the global Peptide Cancer Vaccine market size was valued at XX Million USD in 2024 and is projected to reach XX Million USD by 2032, with a CAGR of XX% (2025-2032). Notably, the China market has changed rapidly in the past few years. By 2024, China's market size is expected to be XX Million USD, representing approximately XX% of the global market share. By 2032, it is anticipated to grow further to XX Million USD, contributing XX% to the worldwide market share.
The major global manufacturers of Peptide Cancer Vaccine include Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Imugene, Sellas, Generex Biotechnology, VAXON Biotech, OncoTherapy Science, ISA Pharmaceuticals etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Peptide Cancer Vaccine. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Peptide Cancer Vaccine market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Peptide Cancer Vaccine market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Peptide Cancer Vaccine industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Manufacturers of Peptide Cancer Vaccine Include:
Boston Biomedical
Ultimovacs
BrightPath Biotherapeutics
TapImmune
Immatics
Imugene
Sellas
Generex Biotechnology
VAXON Biotech
OncoTherapy Science
ISA Pharmaceuticals
Peptide Cancer Vaccine Product Segment Include:
ITK-1
GRN-1201
TPIV200
TPIV110
UV1
Galinpepimut-S
TARP 27-35
HER-Vaxx
Vx-001
Others
Peptide Cancer Vaccine Product Application Include:
Breast Cancer
Lung Cancer
Melanoma
Prostate Cancer
Others
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends
Chapter 2: Global Peptide Cancer Vaccine Industry PESTEL Analysis
Chapter 3: Global Peptide Cancer Vaccine Industry Porter’s Five Forces Analysis
Chapter 4: Global Peptide Cancer Vaccine Major Regional Market Size (Revenue, Sales, Price) and Forecast Analysis
Chapter 5: Global Peptide Cancer Vaccine Market Size and Forecast by Type and Application Analysis
Chapter 6: North America Peptide Cancer Vaccine Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 7: Europe Peptide Cancer Vaccine Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 8: China Peptide Cancer Vaccine Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 9: APAC (Excl. China) Peptide Cancer Vaccine Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 10: Latin America Peptide Cancer Vaccine Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 11: Middle East and Africa Peptide Cancer Vaccine Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 12: Global Peptide Cancer Vaccine Competitive Analysis of Key Manufacturers (Sales, Revenue, Market Share, Price, Regional Distribution and Industry Concentration)
Chapter 13: Key Company Profiles (Product Portfolio, Sales, Revenue, Price and Gross Margin)
Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers
Chapter 15: Research Findings and Conclusion
Chapter 16: Methodology and Data Sources
Table of Contents
170 Pages
- 1 Peptide Cancer Vaccine Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 Peptide Cancer Vaccine Product by Type
- 1.2.1 ITK-1
- 1.2.2 GRN-1201
- 1.2.3 TPIV200
- 1.2.4 TPIV110
- 1.2.5 UV1
- 1.2.6 Galinpepimut-S
- 1.2.7 TARP 27-35
- 1.2.8 HER-Vaxx
- 1.2.9 Vx-001
- 1.2.10 Others
- 1.3 Peptide Cancer Vaccine Product by Application
- 1.3.1 Breast Cancer
- 1.3.2 Lung Cancer
- 1.3.3 Melanoma
- 1.3.4 Prostate Cancer
- 1.3.5 Others
- 1.4 Global Peptide Cancer Vaccine Market Revenue and Sales Analysis
- 1.4.1 Global Peptide Cancer Vaccine Revenue Market Size Analysis (2020-2032)
- 1.4.2 Global Peptide Cancer Vaccine Sales Market Size Analysis (2020-2032)
- 1.4.3 Global Peptide Cancer Vaccine Market Sales Price Trend Analysis (2020-2032)
- 1.5 Peptide Cancer Vaccine Industry Trends and Innovation
- 1.5.1 Peptide Cancer Vaccine Industry Trends and Innovation
- 1.5.2 Peptide Cancer Vaccine Market Drivers and Challenges
- 2 Peptide Cancer Vaccine Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 Peptide Cancer Vaccine Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global Peptide Cancer Vaccine Market Analysis by Regions
- 4.1 Peptide Cancer Vaccine Overall Market: 2024 VS 2025 VS 2032
- 4.2 Global Peptide Cancer Vaccine Revenue and Forecast Analysis (2020-2032)
- 4.2.1 Global Peptide Cancer Vaccine Revenue and Market Share by Region (2020-2025)
- 4.2.2 Global Peptide Cancer Vaccine Revenue and Market Share Forecast by Region (2026-2032)
- 4.3 Global Peptide Cancer Vaccine Sales and Forecast Analysis (2020-2032)
- 4.3.1 Global Peptide Cancer Vaccine Sales and Market Share by Region (2020-2025)
- 4.3.2 Global Peptide Cancer Vaccine Sales Forecast by Region (2026-2032)
- 4.4 Global Peptide Cancer Vaccine Sales Price Trend Analysis (2020-2032)
- 5 Global Peptide Cancer Vaccine Market Size by Type and Application
- 5.1 Global Peptide Cancer Vaccine Market Size by Type
- 5.1.1 Global Peptide Cancer Vaccine Revenue and Forecast Analysis by Type (2020-2032)
- 5.1.2 Global Peptide Cancer Vaccine Sales and Forecast Analysis by Type (2020-2032)
- 5.2 Global Peptide Cancer Vaccine Market Size by Application
- 5.2.1 Global Peptide Cancer Vaccine Revenue and Forecast Analysis by Application (2020-2032)
- 5.2.2 Global Peptide Cancer Vaccine Sales and Forecast Analysis by Application (2020-2032)
- 6 North America
- 6.1 North America Peptide Cancer Vaccine Market Size and Growth Rate Analysis (2020-2032)
- 6.2 North America Key Manufacturers Analysis
- 6.3 North America Peptide Cancer Vaccine Market Size by Type
- 6.3.1 North America Peptide Cancer Vaccine Sales by Type (2020-2032)
- 6.3.2 North America Peptide Cancer Vaccine Revenue by Type (2020-2032)
- 6.4 North America Peptide Cancer Vaccine Market Size by Application
- 6.4.1 North America Peptide Cancer Vaccine Sales by Application (2020-2032)
- 6.4.2 North America Peptide Cancer Vaccine Revenue by Application (2020-2032)
- 6.5 North America Peptide Cancer Vaccine Market Size by Country
- 6.5.1 US
- 6.5.2 Canada
- 7 Europe
- 7.1 Europe Peptide Cancer Vaccine Market Size and Growth Rate Analysis (2020-2032)
- 7.2 Europe Key Manufacturers Analysis
- 7.3 Europe Peptide Cancer Vaccine Market Size by Type
- 7.3.1 Europe Peptide Cancer Vaccine Sales by Type (2020-2032)
- 7.3.2 Europe Peptide Cancer Vaccine Revenue by Type (2020-2032)
- 7.4 Europe Peptide Cancer Vaccine Market Size by Application
- 7.4.1 Europe Peptide Cancer Vaccine Sales by Application (2020-2032)
- 7.4.2 Europe Peptide Cancer Vaccine Revenue by Application (2020-2032)
- 7.5 Europe Peptide Cancer Vaccine Market Size by Country
- 7.5.1 Germany
- 7.5.2 France
- 7.5.3 United Kingdom
- 7.5.4 Italy
- 7.5.5 Spain
- 7.5.6 Benelux
- 8 China
- 8.1 China Peptide Cancer Vaccine Market Size and Growth Rate Analysis (2020-2032)
- 8.2 China Key Manufacturers Analysis
- 8.3 China Peptide Cancer Vaccine Market Size by Type
- 8.3.1 China Peptide Cancer Vaccine Sales by Type (2020-2032)
- 8.3.2 China Peptide Cancer Vaccine Revenue by Type (2020-2032)
- 8.4 China Peptide Cancer Vaccine Market Size by Application
- 8.4.1 China Peptide Cancer Vaccine Sales by Application (2020-2032)
- 8.4.2 China Peptide Cancer Vaccine Revenue by Application (2020-2032)
- 9 APAC (excl. China)
- 9.1 APAC (excl. China) Peptide Cancer Vaccine Market Size and Growth Rate Analysis (2020-2032)
- 9.2 APAC (excl. China) Key Manufacturers Analysis
- 9.3 APAC (excl. China) Peptide Cancer Vaccine Market Size by Type
- 9.3.1 APAC (excl. China) Peptide Cancer Vaccine Sales by Type (2020-2032)
- 9.3.2 APAC (excl. China) Peptide Cancer Vaccine Revenue by Type (2020-2032)
- 9.4 APAC (excl. China) Peptide Cancer Vaccine Market Size by Application
- 9.4.1 APAC (excl. China) Peptide Cancer Vaccine Sales by Application (2020-2032)
- 9.4.2 APAC (excl. China) Peptide Cancer Vaccine Revenue by Application (2020-2032)
- 9.5 APAC (excl. China) Peptide Cancer Vaccine Market Size by Country
- 9.5.1 Japan
- 9.5.2 South Korea
- 9.5.3 India
- 9.5.4 Australia
- 9.5.5 Southeast Asia
- 10 Latin America
- 10.1 Latin America Peptide Cancer Vaccine Market Size and Growth Rate Analysis (2020-2032)
- 10.2 Latin America Key Manufacturers Analysis
- 10.3 Latin America Peptide Cancer Vaccine Market Size by Type
- 10.3.1 Latin America Peptide Cancer Vaccine Sales by Type (2020-2032)
- 10.3.2 Latin America Peptide Cancer Vaccine Revenue by Type (2020-2032)
- 10.4 Latin America Peptide Cancer Vaccine Market Size by Application
- 10.4.1 Latin America Peptide Cancer Vaccine Sales by Application (2020-2032)
- 10.4.2 Latin America Peptide Cancer Vaccine Revenue by Application (2020-2032)
- 10.5 Latin America Peptide Cancer Vaccine Market Size by Country
- 10.6 Latin America Peptide Cancer Vaccine Market Size by Country
- 10.6.1 Mexico
- 10.6.2 Brazil
- 11 Middle East & Africa
- 11.1 Middle East & Africa Peptide Cancer Vaccine Market Size and Growth Rate Analysis (2020-2032)
- 11.2 Middle East & Africa Key Manufacturers Analysis
- 11.3 Middle East & Africa Peptide Cancer Vaccine Market Size by Type
- 11.3.1 Middle East & Africa Peptide Cancer Vaccine Sales by Type (2020-2032)
- 11.3.2 Middle East & Africa Peptide Cancer Vaccine Revenue by Type (2020-2032)
- 11.4 Middle East & Africa Peptide Cancer Vaccine Market Size by Application
- 11.4.1 Middle East & Africa Peptide Cancer Vaccine Sales by Application (2020-2032)
- 11.4.2 Middle East & Africa Peptide Cancer Vaccine Revenue by Application (2020-2032)
- 11.5 Middle East Peptide Cancer Vaccine Market Size by Country
- 11.5.1 Saudi Arabia
- 11.5.2 South Africa
- 12 Competition by Manufacturers
- 12.1 Global Peptide Cancer Vaccine Market Sales, Revenue and Price by Key Manufacturers (2021-2025)
- 12.1.1 Global Peptide Cancer Vaccine Market Sales by Key Manufacturers (2021-2025)
- 12.1.2 Global Peptide Cancer Vaccine Market Revenue by Key Manufacturers (2021-2025)
- 12.1.3 Global Peptide Cancer Vaccine Average Sales Price by Manufacturers (2021-2025)
- 12.2 Peptide Cancer Vaccine Competitive Landscape Analysis and Market Dynamic
- 12.2.1 Peptide Cancer Vaccine Competitive Landscape Analysis
- 12.2.2 Global Key Manufacturers Headquarter Location and Key Area Sales
- 12.2.3 Market Dynamic
- 13 Key Companies Analysis
- 13.1 Boston Biomedical
- 13.1.1 Boston Biomedical Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.1.2 Boston Biomedical Peptide Cancer Vaccine Product Portfolio
- 13.1.3 Boston Biomedical Peptide Cancer Vaccine Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 13.2 Ultimovacs
- 13.2.1 Ultimovacs Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.2.2 Ultimovacs Peptide Cancer Vaccine Product Portfolio
- 13.2.3 Ultimovacs Peptide Cancer Vaccine Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 13.3 BrightPath Biotherapeutics
- 13.3.1 BrightPath Biotherapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.3.2 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
- 13.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 13.4 TapImmune
- 13.4.1 TapImmune Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.4.2 TapImmune Peptide Cancer Vaccine Product Portfolio
- 13.4.3 TapImmune Peptide Cancer Vaccine Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 13.5 Immatics
- 13.5.1 Immatics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.5.2 Immatics Peptide Cancer Vaccine Product Portfolio
- 13.5.3 Immatics Peptide Cancer Vaccine Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 13.6 Imugene
- 13.6.1 Imugene Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.6.2 Imugene Peptide Cancer Vaccine Product Portfolio
- 13.6.3 Imugene Peptide Cancer Vaccine Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 13.7 Sellas
- 13.7.1 Sellas Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.7.2 Sellas Peptide Cancer Vaccine Product Portfolio
- 13.7.3 Sellas Peptide Cancer Vaccine Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 13.8 Generex Biotechnology
- 13.8.1 Generex Biotechnology Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.8.2 Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
- 13.8.3 Generex Biotechnology Peptide Cancer Vaccine Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 13.9 VAXON Biotech
- 13.9.1 VAXON Biotech Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.9.2 VAXON Biotech Peptide Cancer Vaccine Product Portfolio
- 13.9.3 VAXON Biotech Peptide Cancer Vaccine Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 13.10 OncoTherapy Science
- 13.10.1 OncoTherapy Science Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.10.2 OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
- 13.10.3 OncoTherapy Science Peptide Cancer Vaccine Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 13.11 ISA Pharmaceuticals
- 13.11.1 ISA Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.11.2 ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
- 13.11.3 ISA Pharmaceuticals Peptide Cancer Vaccine Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 14 Industry Chain Analysis
- 14.1 Peptide Cancer Vaccine Industry Chain Analysis
- 14.2 Peptide Cancer Vaccine Industry Raw Material and Suppliers Analysis
- 14.2.1 Peptide Cancer Vaccine Key Raw Material Supply Analysis
- 14.2.2 Raw Material Suppliers and Contact Information
- 14.3 Peptide Cancer Vaccine Typical Downstream Customers
- 14.4 Peptide Cancer Vaccine Sales Channel Analysis
- 15 Research Findings and Conclusion
- 16 Methodology and Data Source
- 16.1 Methodology/Research Approach
- 16.2 Research Scope
- 16.3 Benchmarks and Assumptions
- 16.4 Date Source
- 16.4.1 Primary Sources
- 16.4.2 Secondary Sources
- 16.5 Data Cross Validation
- 16.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
